Rosacea by the numbers

Size: px
Start display at page:

Download "Rosacea by the numbers"

Transcription

1 AMERICAN ACADEMY OF DERMATOLOGY SKIN DISEASE BRIEFS Rosacea by the numbers Rosacea is among 24 skin diseases or disease categories examined in the Burden of Skin Disease report commissioned by the American Academy of Dermatology. The report examined prevalence, economic burdens, and mortality for skin disease in the U.S. using 2013 health care claims data drawn from insurance enrollment and claims databases and found that: 84.5 million Americans one in four saw a physician for skin disease; 50% of them are over 65 and have an average of 2.2 skin conditions. Skin disease cost the U.S. health care system $75 billion in medical, preventative, and prescription and non-prescription drug costs. One in three Americans were seen by dermatologists, who collaborate with other physicians throughout the health care system in caring for these patients. More than 1.6 million Americans sought medical treatment for rosacea in 2013, a similar number to those affected by psoriasis in the same year. Rosacea: Is prevalent in adults of all ages. Cost $165 million in medical treatment in Patients and their caregivers experience substantial loss of productivity, totaling $78 million. The charts that follow provide topline data on how rosacea contributes to the overall burden of skin disease. The full report includes data on prescription and non-prescription drug costs, and how age and insurance status and provider relate to the burden associated with rosacea and skin disease broadly. To purchase the report visit

2 Prevalance NUMBER OF CARED-FOR INDIVIDUALS 30,000,000 25,000,000 20,000,000 15,000,000 10,000,000 5,000, ,613,610 NON-CANCEROUS SKIN GROWTHS* VIRAL AND FUNGAL WOUNDS AND BURNS CONTACT DERMATITIS * This category is clinically broad in nature and includes, among other diseases: benign neoplasms, melanocytic nevi PATIENTS BY AGE* 45.0% 40.0% 41.1% 35.0% 30.0% 35.0% 25.0% 20.0% 15.0% 20.8% 0.34% 10.0% 5.0% 0.0% 3.2% *Percentage of rosacea patients seen by a physician by age group.

3 Cost TOTAL MEDICAL COST* (IN MILLIONS USD) $9,000 $8,000 $7,000 $6,000 $5,000 $4,000 $3,000 $8,135 $7,015 $6,398 $6,052 $5,442 $2,000 $1,000 $0 $165 NON-CANCEROUS SKIN GROWTHS** WOUNDS AND BURNS SKIN CANCER*** ULCERS HAIR AND NAIL DISORDERS * In millions of dollars compared to most costly skin diseases * * This category is clinically broad in nature and includes, among other diseases: benign neoplasms, melanocytic nevi *** Represents combined data for melanoma and nonmelanoma skin cancer. COST OF SKIN DISEASE PER AFFECTED PERSON* $3, $3, $2, $2, $1, $1, $ $0.00 $ LYMPHOMA SKIN CANCER** ULCERS CONNECTIVE TISSUE BULLOUS *Compared with most costly skin diseases. ** Represents combined data for melanoma and nonmelanoma skin cancer.

4 Life Impact LOST PRODUCTIVITY (OPPORTUNITY COST)* $2,500 (IN MILLIONS USD) $2,000 $1,500 $1,000 $1,924 $1,570 $1,413 $940 $699 $500 $0 $78 NON-CANCEROUS WOUNDS SKIN GROWTHS** AND BURNS VIRAL AND FUNGAL CONTACT DERMATITIS * Time lost by patients and/or caregivers multiplied by average wages in 2013 ($192/day); In millions of dollars compared with skin diseases leading to the most loss of productivity * *This category is clinically broad in nature and includes, among other diseases: benign neoplasms, melanocytic nevi

5 This information is intended for personal/noncommercial use and may not be reproduced in any form by any means (electronic, mechanical, or other) or held in any information storage and retrieval systems without written permission from the publisher. Commercial use or distribution For information on obtaining copies of this publication or to license the content for distribution, please visit for details and to complete an application.

Contact dermatitis by the numbers

Contact dermatitis by the numbers AMERICAN ACADEMY OF DERMATOLOGY SKIN DISEASE BRIEFS Contact dermatitis by the numbers Contact dermatitis is among 24 skin diseases or disease categories examined in the Burden of Skin Disease report commissioned

More information

Psoriasis by the numbers

Psoriasis by the numbers AMERICAN ACADEMY OF DERMATOLOGY SKIN DISEASE BRIEFS Psoriasis by the numbers Psoriasis is among 24 skin diseases or disease categories examined in the Burden of Skin Disease report commissioned by the

More information

Acne by the numbers. The charts that follow provide topline data on how acne contributes to the overall burden of skin disease.

Acne by the numbers. The charts that follow provide topline data on how acne contributes to the overall burden of skin disease. AMERICAN ACADEMY OF DERMATOLOGY SKIN DISEASE BRIEFS Acne by the numbers Acne is among 24 skin diseases or disease categories examined in the Burden of Skin Disease report commissioned by the American Academy

More information

Hair and nail disorders by the numbers

Hair and nail disorders by the numbers AMERICAN ACADEMY OF DERMATOLOGY SKIN DISEASE BRIEFS Hair and nail disorders by the numbers Hair and nail disorders are among 24 skin diseases or disease categories examined in the Burden of Skin Disease

More information

Skin infections by the numbers

Skin infections by the numbers AMERICAN ACADEMY OF DERMATOLOGY SKIN DISEASE BRIEFS Skin infections by the numbers Skin infections are among 24 skin diseases or disease categories examined in the Burden of Skin Disease report commissioned

More information

Bullous diseases by the numbers

Bullous diseases by the numbers AMERICAN ACADEMY OF DERMATOLOGY SKIN DISEASE BRIEFS Bullous diseases by the numbers Bullous diseases are among 24 skin diseases or disease categories examined in the Burden of Skin Disease report commissioned

More information

Connective tissue diseases by the numbers

Connective tissue diseases by the numbers AMERICAN ACADEMY OF DERMATOLOGY SKIN DISEASE BRIEFS Connective tissue diseases by the numbers Connective tissue diseases are among 24 skin diseases or disease categories examined in the Burden of Skin

More information

Skin cancer by the numbers

Skin cancer by the numbers AMERICAN ACADEMY OF DERMATOLOGY DISEASE BRIEFS Skin cancer by the numbers Melanoma and nonmelanoma (basal and squamous cell carcinoma) skin cancers are among 24 skin diseases or disease categories examined

More information

Congenital abnormalities. by the numbers

Congenital abnormalities. by the numbers AMERICAN ACADEMY OF DERMATOLOGY SKIN DISEASE BRIEFS Congenital abnormalities by the numbers Congenital abnormalities are among 24 skin diseases or disease categories examined in the Burden of Skin Disease

More information

Re: MassHealth Section 1115 Demonstration Waiver Amendment Request, Section 4 ( Waiver Request )

Re: MassHealth Section 1115 Demonstration Waiver Amendment Request, Section 4 ( Waiver Request ) October 20, 2017 Eric Hargan Acting Secretary Department of Health and Human Services Hubert H. Humphrey Building 200 Independence Avenue, SW Washington, D.C. 20201 Re: MassHealth Section 1115 Demonstration

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Policy: Atopic Dermatitis and Topical Antipsoriatics Reference Number: TCHP.PHAR.18004 Effective Date: 01.01.18 Last Review Date: 10.12.18 Line of Business: Oregon Health Plan Revision Log See Important

More information

Screening for malignant melanoma: a cost-effectiveness analysis Freedberg K A, Geller A C, Miller D R, Lew R A, Koh H K

Screening for malignant melanoma: a cost-effectiveness analysis Freedberg K A, Geller A C, Miller D R, Lew R A, Koh H K Screening for malignant melanoma: a cost-effectiveness analysis Freedberg K A, Geller A C, Miller D R, Lew R A, Koh H K Record Status This is a critical abstract of an economic evaluation that meets the

More information

VACAVILLE DERMATOLOGY

VACAVILLE DERMATOLOGY Connecting the Dots on those Spots NANDAN V. KAMATH, M.D. VACAVILLE DERMATOLOGY Sources All of the photos were taken with permission from the Dermnet NZ website - Dermnet New Zealand after communicating

More information

DESCRIPTIONS FOR MED 3 ROTATIONS Dermatology A3S

DESCRIPTIONS FOR MED 3 ROTATIONS Dermatology A3S Regardless of your future field of practice, you will be exposed to a considerable amount of dermatology and this rotation provides you the chance to see a range of skin diseases. You will have the opportunity

More information

Impact of Chronic Conditions on Health-Related Quality of Life

Impact of Chronic Conditions on Health-Related Quality of Life BURDEN OF ILLNESS Overview Impact of Chronic Conditions on Health-Related Quality of Life Chronic joint pain conditions have an important impact on health-related quality of life Note: a larger negative

More information

BL-5010P A NOVEL PRE-FILLED APPLICATOR FOR THE NON-SURGICAL REMOVAL OF SKIN LESIONS

BL-5010P A NOVEL PRE-FILLED APPLICATOR FOR THE NON-SURGICAL REMOVAL OF SKIN LESIONS BL-5010P A NOVEL PRE-FILLED APPLICATOR FOR THE NON-SURGICAL REMOVAL OF SKIN LESIONS 25 Skin lesions Miri Seiberg, PhD 26 Skin lesions A part of the skin that has an abnormal growth or appearance compared

More information

COLLOIDAL SILVER. Compiled by. Campbell M Gold (2009) CMG Archives --()-- IMPORTANT

COLLOIDAL SILVER. Compiled by. Campbell M Gold (2009) CMG Archives  --()-- IMPORTANT COLLOIDAL SILVER Compiled by Campbell M Gold (2009) CMG Archives http://www.campbellmgold.com IMPORTANT The health information contained herein is not meant as a substitute for advice from your physician,

More information

What are the functions of the integumentary system? What are some disorders of the integumentary system?

What are the functions of the integumentary system? What are some disorders of the integumentary system? Essential Questions: What are the functions of the integumentary system? What are some disorders of the integumentary system? How are integumentary system disorders treated? How do you relate the integumentary

More information

Asthma Management and the Allergist

Asthma Management and the Allergist Asthma Management and the Allergist Better Outcomes at Lower Cost Executive Summary AllergyandAsthmaRelief.org college.acaai.org/betteroutcomeslowercosts A substantial and growing body of published clinical

More information

Undergraduate Dermatology Curriculum July 2016

Undergraduate Dermatology Curriculum July 2016 Undergraduate Dermatology Curriculum July 2016 British Association of Dermatologists Introduction This document is the 2016 revised dermatology undergraduate curriculum (UK) from the British Association

More information

Calculate a Fraction of a Whole Number

Calculate a Fraction of a Whole Number Calculate a Fraction of a Whole Number Objective: Calculate a fraction of a whole number Terms and Conditions To the best of the producer's knowledge, the academic content of this resource is accurate

More information

Patricia C. McCormack, M.D., F.A.A.D.

Patricia C. McCormack, M.D., F.A.A.D. Patricia C. McCormack, M.D., F.A.A.D. Diplomate of the American Board of Dermatology Adult & Pediatric Dermatology www.patriciamccormackmd.com PATIENT INFORMATION Today s date: Last name: First name: of

More information

Contribution of health care factors to the burden of skin disease in the United States

Contribution of health care factors to the burden of skin disease in the United States FROM THE ACADEMY Contribution of health care factors to the burden of disease in the United States HenryW.Lim,MD, a ScottA.B.Collins,MD, b Jack S. Resneck, Jr, MD, c Jean L. Bolognia, MD, d Julie A. Hodge,

More information

Dermatology Syllabus for 5th Year Med Students

Dermatology Syllabus for 5th Year Med Students Hawler Medical University College of Medicine Department of medicine 2011-2012 Dermatology Syllabus for 5th Year Med Students Course Information: Course Title : Dermatology Credit Hours : Time Theoretical:

More information

ETG Analyzer Report. Your Practice # Episodes. Mkt Share Mkt Volume WHIO Dermatology 575 Acne 746 $508 1,698 $

ETG Analyzer Report. Your Practice # Episodes. Mkt Share Mkt Volume WHIO Dermatology 575 Acne 746 $508 1,698 $ ETG Analyzer Report Practice: Practice Group: Badger County Severity: Level 1 Payers: Commercial Episode Types: Complete Claims: Full Claims Outliers: No Outliers DMV6 Created: April 1, 2010 March 31,

More information

WR SKIN. DERMATOLOGY

WR SKIN. DERMATOLOGY WR SKIN. DERMATOLOGY 1 Societies 11 History 13 Dictionaries. Encyclopaedias. Bibliographies Use for general works only. Classify with specific aspect 15 Classification. Nomenclature 16 Tables. Statistics

More information

Principles of Anatomy and Physiology

Principles of Anatomy and Physiology Principles of Anatomy and Physiology 14 th Edition CHAPTER 5 The Integumentary System Introduction The organs of the integumentary system include the skin and its accessory structures including hair, nails,

More information

UNDERSTANDING ATOPIC DERMATITIS IN THE US

UNDERSTANDING ATOPIC DERMATITIS IN THE US Key points: Resources for training general practitioners to treat atopic dermatitis (AD) remain sparse and inconsistent. A lack of comprehensive data makes it difficult to assess the prevalence of AD in

More information

Clinical Policy: Laser Therapy for Skin Conditions Reference Number: CP.MP.123 Last Review Date: 08/17

Clinical Policy: Laser Therapy for Skin Conditions Reference Number: CP.MP.123 Last Review Date: 08/17 Clinical Policy: Laser Therapy for Skin Conditions Reference Number: CP.MP.123 Last Review Date: 08/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory

More information

Table 1: One Year Net Survival Rates for All Cancers Excluding Non-Melanoma Skin Cancer:

Table 1: One Year Net Survival Rates for All Cancers Excluding Non-Melanoma Skin Cancer: Task 1: Draw a bar chart of the following data. All the data must be on one graph. The data shows yearly survival rates for all types of cancers combined (except non-melanoma skin cancer). Hint: Each period

More information

Punch 1/25/2017. Coding for Biopsies. Jeffrey D. Lehrman, DPM, FASPS, FACFAS, MAPWCA. APMA Coding Committee. Editorial Advisory Board, WOUNDS

Punch 1/25/2017. Coding for Biopsies. Jeffrey D. Lehrman, DPM, FASPS, FACFAS, MAPWCA. APMA Coding Committee. Editorial Advisory Board, WOUNDS Coding for Biopsies Jeffrey D. Lehrman, DPM, FASPS, FACFAS, MAPWCA APMA Coding Committee Editorial Advisory Board, WOUNDS Board of Directors, American Society of Podiatric Surgeons Board of Directors,

More information

Clinical Policy: Apremilast (Otezla) Reference Number: CP.PHAR.245 Effective Date: 08/16 Last Review Date 08/17

Clinical Policy: Apremilast (Otezla) Reference Number: CP.PHAR.245 Effective Date: 08/16 Last Review Date 08/17 Clinical Policy: (Otezla) Reference Number: CP.PHAR.245 Effective Date: 08/16 Last Review Date 08/17 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

A Review of Medical Malpractice Claims from the CRICO Comparative Benchmarking System

A Review of Medical Malpractice Claims from the CRICO Comparative Benchmarking System A Review of Medical Malpractice Claims from the CRICO Comparative Benchmarking System (CBS: a national database of medical malpractice claims from captive & commercial insurers across the US ) Note: I

More information

The Healthcare Cost of Symptomatic Congenital CMV Disease in Privately Insured US Children: Estimates from Administrative Claims Data

The Healthcare Cost of Symptomatic Congenital CMV Disease in Privately Insured US Children: Estimates from Administrative Claims Data National Center on Birth Defects and Developmental Disabilities The Healthcare Cost of Symptomatic Congenital CMV Disease in Privately Insured US Children: Estimates from Administrative Claims Data Scott

More information

KEY MESSAGES. Psoriasis patients are more prone to cardiovascular diseases, stroke, lymphoma and non-melanoma skin cancers, and increased mortality.

KEY MESSAGES. Psoriasis patients are more prone to cardiovascular diseases, stroke, lymphoma and non-melanoma skin cancers, and increased mortality. KEY MESSAGES Psoriasis is a genetically determined, systemic immune-mediated chronic inflammatory disease that affects primarily the skin and joints. Psoriasis Vulgaris is characterised by well-demarcated

More information

DERMATOLOGY ROTATION: COMPETENCY-BASED GOALS AND OBJECTIVES

DERMATOLOGY ROTATION: COMPETENCY-BASED GOALS AND OBJECTIVES UNC DIVISION OF PLASTIC AND RECONSTRUCTIVE SURGERY DERMATOLOGY ROTATION: COMPETENCY-BASED GOALS AND OBJECTIVES MEDICAL KNOWLEDGE A. Anatomy/Physiology/Embryology Goal: The resident will have knowledge

More information

Original Article. Abstract. Introduction

Original Article. Abstract. Introduction Original Article The prevalence of skin diseases among the geriatric patients in Eastern Turkey Serap Gunes Bilgili, 1 Ayse Serap Karadag, 2 Hatice Uce Ozkol, 3 Omer Calka, 4 Necmettin Akdeniz 5 Department

More information

THE COST OF DIABETES IN ALBERTA

THE COST OF DIABETES IN ALBERTA THE COST OF DIABETES IN ALBERTA The Alberta Diabetes Cost Model 1 In 2009, the Canadian Diabetes Association commissioned a report, An Economic Tsunami: the Cost of Diabetes in Canada, to determine the

More information

Clinic Clinic Information Suitable for Referral Not Suitable for Referral

Clinic Clinic Information Suitable for Referral Not Suitable for Referral PBC Services Clinic Clinic Information Suitable for Referral Not Suitable for Referral Diabetes One Off Clinic Donnington Medical The Health Centre, Wrekin Drive Donnington TF2 8EA Contact: Bryan Henshall

More information

Gastric ulcers at endoscopy: brush, biopsy, or both Sadowski D C, Rabeneck L

Gastric ulcers at endoscopy: brush, biopsy, or both Sadowski D C, Rabeneck L Gastric ulcers at endoscopy: brush, biopsy, or both Sadowski D C, Rabeneck L Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract

More information

Source of effectiveness data The effectiveness evidence was derived from a review of published studies.

Source of effectiveness data The effectiveness evidence was derived from a review of published studies. Cost and cost effectiveness of venous and pressure ulcer protocols of care Kerstein M D, Gemmen E, van Rijswijk L, Lyder C H, Phillips T, Xakellis G, Golden K, Harrington C Record Status This is a critical

More information

Source of effectiveness data The effectiveness evidence was derived from a systematic review of published studies.

Source of effectiveness data The effectiveness evidence was derived from a systematic review of published studies. Pharmacoeconomic analysis of ciclopirox nail lacquer solution 8% and the new oral antifungal agents used to treat dermatophyte toe onychomycosis in the United States Gupta A K Record Status This is a critical

More information

Cost of Diabetes. Laura Keller Director State Advocacy AK CO HI ID MT ND OR SD WA WY

Cost of Diabetes. Laura Keller Director State Advocacy AK CO HI ID MT ND OR SD WA WY Cost of Diabetes Laura Keller Director State Advocacy AK CO HI ID MT ND OR SD WA WY Christopher Stanley, MD, MBA American Diabetes Association Colorado Advocacy Chair Vice President of Population Health

More information

Cancer Disparities in Arkansas: An Uneven Distribution. Prepared by: Martha M. Phillips, PhD, MPH, MBA. For the Arkansas Cancer Coalition

Cancer Disparities in Arkansas: An Uneven Distribution. Prepared by: Martha M. Phillips, PhD, MPH, MBA. For the Arkansas Cancer Coalition Cancer Disparities in Arkansas: An Uneven Distribution Prepared by: Martha M. Phillips, PhD, MPH, MBA For the Arkansas Cancer Coalition Table of Contents Page Burden of Cancer 3 Cancer Disparities 3 Cost

More information

The impact of pharmaceutical innovation on New Zealand cancer patients

The impact of pharmaceutical innovation on New Zealand cancer patients The impact of pharmaceutical innovation on New Zealand cancer patients Frank R. Lichtenberg, Ph.D Columbia University and National Bureau of Economic Research New medicines have helped people with cancer

More information

VARIATIONS IN PRICES AND REIMBURSEMENT OF MEDICINES IN THE EUROPEAN UNION

VARIATIONS IN PRICES AND REIMBURSEMENT OF MEDICINES IN THE EUROPEAN UNION VARIATIONS IN PRICES AND REIMBURSEMENT OF MEDICINES IN THE EUROPEAN UNION A snapshot of data on amoxicillin, budesonide, losartan and salbutamol in eight European Union Member States Report INTRODUCTION

More information

Pharmacy Prep. Qualifying Pharmacy Review

Pharmacy Prep. Qualifying Pharmacy Review Pharmacy Prep 2014 Misbah Biabani, Ph.D Director, Tips Review Centres 5460 Yonge St. Suites 209 & 210 Toronto ON M2N 6K7, Canada Luay Petros, R.Ph Pharmacy Manager, Wal-Mart, Canada 1 Disclaimer Your use

More information

DERMOSCOPY. October 23-24, 2015 INTERMEDIATE COURSE. 11th Annual. New York. is pleased to announce:

DERMOSCOPY. October 23-24, 2015 INTERMEDIATE COURSE. 11th Annual.  New York. is pleased to announce: is pleased to announce: October 23-24, 2015 11th Annual INTERMEDIATE COURSE COURSE LOCATION Memorial Sloan Kettering Cancer Center ZUCKERMAN RESEARCH CENTER 417 East 68th Street between First and York

More information

Clinical profile of skin diseases in accident and emergency department attenders

Clinical profile of skin diseases in accident and emergency department attenders Hong Kong J. Dermatol. Venereol. (2007) 15, 4-9 Original Article Clinical profile of skin diseases in accident and emergency department attenders CY Chan, KL Kam, CA Graham, TH Rainer, NM Luk Skin problems

More information

A PRACTICAL APPROACH TO ATYPICAL MELANOCYTIC LESIONS BIJAN HAGHIGHI M.D, DIRECTOR OF DERMATOPATHOLOGY, ST. JOSEPH HOSPITAL

A PRACTICAL APPROACH TO ATYPICAL MELANOCYTIC LESIONS BIJAN HAGHIGHI M.D, DIRECTOR OF DERMATOPATHOLOGY, ST. JOSEPH HOSPITAL A PRACTICAL APPROACH TO ATYPICAL MELANOCYTIC LESIONS BIJAN HAGHIGHI M.D, DIRECTOR OF DERMATOPATHOLOGY, ST. JOSEPH HOSPITAL OBJECTIVES Discuss current trends and changing concepts in our understanding of

More information

Pertussis in adolescents and adults: should we vaccinate Lee G M, LeBaron C, Murphy T V, Lett S, Schauer S, Lieu T A

Pertussis in adolescents and adults: should we vaccinate Lee G M, LeBaron C, Murphy T V, Lett S, Schauer S, Lieu T A Pertussis in adolescents and adults: should we vaccinate Lee G M, LeBaron C, Murphy T V, Lett S, Schauer S, Lieu T A Record Status This is a critical abstract of an economic evaluation that meets the criteria

More information

Dates to which data relate The effectiveness data were gathered from 1 July 1996 to 20 June No price year was reported.

Dates to which data relate The effectiveness data were gathered from 1 July 1996 to 20 June No price year was reported. Impact of first-line vs second-line antibiotics for the treatment of acute uncomplicated sinusitis Piccirillo J F, Mager D E, Frisse M E, Bophy R H, Goggin A Record Status This is a critical abstract of

More information

The cost-effectiveness of screening blood donors for malaria by PCR Shehata N, Kohli M, Detsky A

The cost-effectiveness of screening blood donors for malaria by PCR Shehata N, Kohli M, Detsky A The cost-effectiveness of screening blood donors for malaria by PCR Shehata N, Kohli M, Detsky A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion

More information

Skin is a multilayered organ that covers and protects the body.

Skin is a multilayered organ that covers and protects the body. Section 1: Skin is a multilayered organ that covers and protects the body. K What I Know W What I Want to Find Out L What I Learned Essential Questions What are the four tissue types that are found in

More information

Clinical Policy: Nivolumab (Opdivo) Reference Number: CP.HNMC.27 Effective Date: Last Review Date: Line of Business: Medicaid - HNMC

Clinical Policy: Nivolumab (Opdivo) Reference Number: CP.HNMC.27 Effective Date: Last Review Date: Line of Business: Medicaid - HNMC Clinical Policy: (Opdivo) Reference Number: CP.HNMC.27 Effective Date: 07.01.17 Last Review Date: 02.18 Line of Business: Medicaid - HNMC Revision Log See Important Reminder at the end of this policy for

More information

Health technology Lower-extremity amputation prevention strategies among individuals with diabetes.

Health technology Lower-extremity amputation prevention strategies among individuals with diabetes. Potential economic benefits of lower-extremity amputation prevention strategies in diabetes Ollendorf D A, Kotsanos J G, Wishner W J, Friedman M, Cooper T, Bittoni M, Oster G Record Status This is a critical

More information

Developments in Psoriasis Management Celgene Corporation 07/14 USII-CELG140030

Developments in Psoriasis Management Celgene Corporation 07/14 USII-CELG140030 Developments in Psoriasis Management 2014 Celgene Corporation 07/14 USII-CELG140030 Psoriasis (PsO) Is a Chronic Inflammatory Disease That Can Impact Patients Health-Related Quality of Life PsO is a chronic

More information

Research Award Recipient Survey

Research Award Recipient Survey Research Award Recipient Survey Page 1 of 5 Recipient Name: Dermatology Foundation Research Awards: 1. Current Institutional Affiliation (please specify): Academic Institution: Other: 2. Current Professional

More information

Cost-effectiveness of uterine artery embolization and hysterectomy for uterine fibroids Beinfeld M T, Bosch J L, Isaacson K B, Gazelle G S

Cost-effectiveness of uterine artery embolization and hysterectomy for uterine fibroids Beinfeld M T, Bosch J L, Isaacson K B, Gazelle G S Cost-effectiveness of uterine artery embolization and hysterectomy for uterine fibroids Beinfeld M T, Bosch J L, Isaacson K B, Gazelle G S Record Status This is a critical abstract of an economic evaluation

More information

LIFE INSURANCE COMPANIES TAKE LEAP OF FAITH

LIFE INSURANCE COMPANIES TAKE LEAP OF FAITH LIFE INSURANCE COMPANIES TAKE LEAP OF FAITH Cover for HIV positive and diabetic lives QED Actuaries & Consultants Craig Falconer 1 December 2017 OVERVIEW HIV Product Diabetes Product Key success Factors

More information

REVIEW MANAGEMENT. Clinical Review of Drugs to Reduce the Risk of Cancer CONTENTS

REVIEW MANAGEMENT. Clinical Review of Drugs to Reduce the Risk of Cancer CONTENTS REVIEW MANAGEMENT Clinical Review of Drugs to Reduce the Risk of Cancer CONTENTS PURPOSE BACKGROUND REFERENCES DEFINITIONS AND ACRONYMS POLICY PROCEDURES EFFECTIVE DATE PURPOSE This MAPP describes: The

More information

Dermatology GP Referral Guidelines

Dermatology GP Referral Guidelines Austin Health Dermatology Department holds 5 Clinic sessions to discuss and plan the treatment of with Dermatology conditions. Department of Health clinical urgency categories for specialist clinics Urgent:

More information

US Wound Dressing Market Size, Share, Growth, Industry Analysis, Competitive Strategies and Forescast to 2024 Hexa Research

US Wound Dressing Market Size, Share, Growth, Industry Analysis, Competitive Strategies and Forescast to 2024 Hexa Research US Wound Dressing Market Size, Share, Growth, Industry Analysis, Competitive Strategies and Forescast to 2024 Hexa Research The U.S. wound dressing market size was valued at USD 3.18 billion in 2017. Increasing

More information

ULTRAPROCT OINTMENT ULTRAPROCT SUPPOSITORIES

ULTRAPROCT OINTMENT ULTRAPROCT SUPPOSITORIES APPLICATION FOR RECLASSIFICATION ULTRAPROCT OINTMENT ULTRAPROCT SUPPOSITORIES Part A Classification Change Sought 1. International Non-Proprietary name of Medicine fluocortolone pivalate, fluocortolone

More information

Clinical Policy: Secukinumab (Cosentyx) Reference Number: CP.PHAR.261 Effective Date: 08/16 Last Review Date: 08/17

Clinical Policy: Secukinumab (Cosentyx) Reference Number: CP.PHAR.261 Effective Date: 08/16 Last Review Date: 08/17 Clinical Policy: (Cosentyx) Reference Number: CP.PHAR.261 Effective Date: 08/16 Last Review Date: 08/17 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

Integumentary System

Integumentary System Integumentary System Physiology of Touch Skin: our most sensitive organ Touch: first sense to develop in embryos Most important but most neglected sense How many sensory receptors do we have? (We have

More information

Clinical Policy: Ixekizumab (Taltz) Reference Number: CP.PHAR.257 Effective Date: Last Review Date: 05.18

Clinical Policy: Ixekizumab (Taltz) Reference Number: CP.PHAR.257 Effective Date: Last Review Date: 05.18 Clinical Policy: (Taltz) Reference Number: CP.PHAR.257 Effective Date: 08.01.16 Last Review Date: 05.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

The Cost of Diabetes in NEWFOUNDLAND & LABRADOR

The Cost of Diabetes in NEWFOUNDLAND & LABRADOR The Cost of Diabetes in NEWFOUNDLAND & LABRADOR The Cost of Diabetes in Newfoundland and Labrador The Newfoundland and Labrador Diabetes Cost Model 1 In 2009, the Canadian Diabetes Association commissioned

More information

STUDY. Access to Health Care in Patients With Psoriasis and Psoriatic Arthritis. Data From National Psoriasis Foundation Survey Panels

STUDY. Access to Health Care in Patients With Psoriasis and Psoriatic Arthritis. Data From National Psoriasis Foundation Survey Panels STUDY Access to Health Care in Patients With Psoriasis and Psoriatic Arthritis Data From National Psoriasis Foundation Survey Panels Tina Bhutani, MD; Jillian W. Wong, MS; Bruce F. Bebo Jr, PhD; April

More information

THE COST OF DIABETES IN BRITISH COLUMBIA

THE COST OF DIABETES IN BRITISH COLUMBIA THE COST OF DIABETES IN BRITISH COLUMBIA The British Columbia Diabetes Cost Model 1 In 2009, the Canadian Diabetes Association commissioned a report, An Economic Tsunami: the Cost of Diabetes in Canada,

More information

Regeneron and Sanofi are financial supporters of The Skin Cancer Foundation and collaborated in the development of this article. US-ONC /2018

Regeneron and Sanofi are financial supporters of The Skin Cancer Foundation and collaborated in the development of this article. US-ONC /2018 A D E E P E R L O O K When detected early, most cases of local cutaneous squamous cell carcinoma are easily treated and usually cured. But when they become more advanced, this second most common form of

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: itraconazole (Sporanox) Reference Number: HIM.PA.36 Effective Date: 05/16 Last Review Date: Line of Business: Health Insurance Marketplace Coding Implications Revision Log See Important

More information

Treatment options for diabetic neuropathic foot ulcers: a cost-effectiveness analysis Kantor J, Margolis D J

Treatment options for diabetic neuropathic foot ulcers: a cost-effectiveness analysis Kantor J, Margolis D J Treatment options for diabetic neuropathic foot ulcers: a cost-effectiveness analysis Kantor J, Margolis D J Record Status This is a critical abstract of an economic evaluation that meets the criteria

More information

Information and Data Brief: Venous Leg Ulcers. Find out why a particular quality standard was created and the data behind it

Information and Data Brief: Venous Leg Ulcers. Find out why a particular quality standard was created and the data behind it Information and Data Brief: Venous Leg Ulcers Find out why a particular quality standard was created and the data behind it Quality Standards are: Concise sets of easy-to-understand statements outlining

More information

Clinical Policy: Phototherapy and Photochemotherapy for Dermatological Conditions Reference Number: CP.MP. 441

Clinical Policy: Phototherapy and Photochemotherapy for Dermatological Conditions Reference Number: CP.MP. 441 Clinical Policy: Phototherapy and Photochemotherapy for Dermatological Conditions Reference Number: CP.MP. 441 Effective Date: November 2008 Last Review Date: January 2017 See Important Reminder at the

More information

Research proposal. The impact of medical knowledge accumulation and diffusion on health: evidence from Medline and other N.I.H.

Research proposal. The impact of medical knowledge accumulation and diffusion on health: evidence from Medline and other N.I.H. 1 Research proposal The impact of medical knowledge accumulation and diffusion on health: evidence from Medline and other N.I.H. data Frank R. Lichtenberg Columbia University and National Bureau of Economic

More information

Trends and Challenges: The Kentucky Opioid Crisis. Jason Smith, MD PhD University of Louisville

Trends and Challenges: The Kentucky Opioid Crisis. Jason Smith, MD PhD University of Louisville Trends and Challenges: The Kentucky Opioid Crisis Jason Smith, MD PhD University of Louisville Brief Introduction I am by no means an expert I have no financial disclosures Jokes are meant to be lighthearted

More information

Miami-Dade County Prepaid Dental Health Plan Demonstration: Less Value for State Dollars

Miami-Dade County Prepaid Dental Health Plan Demonstration: Less Value for State Dollars Miami-Dade County Prepaid Dental Health Plan Demonstration: Less Value for State Dollars Analysis commissioned by The Collins Center for Public Policy / Community Voices Miami AUGUST 2006 Author: Burton

More information

Clinical Policy: Apremilast (Otezla) Reference Number: CP.PHAR.245 Effective Date: Last Review Date: Line of Business: HIM, Medicaid

Clinical Policy: Apremilast (Otezla) Reference Number: CP.PHAR.245 Effective Date: Last Review Date: Line of Business: HIM, Medicaid Clinical Policy: (Otezla) Reference Number: CP.PHAR.245 Effective Date: 08.16 Last Review Date: 11.18 Line of Business: HIM, Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

REFERENCE CODE GDHC294DFR PUBLICATION DATE NOVEMBER 2013 PROTOPIC (ATOPIC DERMATITIS) FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC294DFR PUBLICATION DATE NOVEMBER 2013 PROTOPIC (ATOPIC DERMATITIS) FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC294DFR PUBLICATION DATE NOVEMBER 2013 PROTOPIC (ATOPIC DERMATITIS) Executive Summary The below mentioned table presents key metrics for Protopic in the nine major pharmaceutical markets

More information

Basics in Dermoscopy

Basics in Dermoscopy Basics in Dermoscopy Manal Bosseila Professor of Dermatology, Cairo University Member of European Academy Dermatology & Venereology EADV Member of International Dermoscopy Society IDS Member of Aesthetic

More information

15 th Annual South Beach Symposium Clinical + Aesthetic Dermatology Symposium February 9-12, 2017 Miami Beach, Florida

15 th Annual South Beach Symposium Clinical + Aesthetic Dermatology Symposium February 9-12, 2017 Miami Beach, Florida 15 th Annual South Beach Symposium Clinical + Aesthetic Dermatology Symposium February 9-12, 2017 Miami Beach, Florida 8:00 am 7:00 pm Registration Desk Open Thursday, February 09, 2017 8:30 am 3:00 pm

More information

9.0 ANNUAL SPRING DERMATOLOGY REVIEW 2017 APR 28-29, 2017 FRI-SAT WHO SHOULD ATTEND UBC ROBSON SQUARE VANCOUVER BC. Family Physicians Dermatologists

9.0 ANNUAL SPRING DERMATOLOGY REVIEW 2017 APR 28-29, 2017 FRI-SAT WHO SHOULD ATTEND UBC ROBSON SQUARE VANCOUVER BC. Family Physicians Dermatologists 9.0 MOC SECTION 1 MAINPRO+ ANNUAL SPRING DERMATOLOGY REVIEW 2017 APR 28-29, 2017 FRI-SAT UBC ROBSON SQUARE VANCOUVER BC WHO SHOULD ATTEND Family Physicians Dermatologists Allergists & Immunologists Residents

More information

REFERENCE CODE GDHC295DFR PUBLICATION DATE NOVEMBER 2013 ELIDEL (ATOPIC DERMATITIS) FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC295DFR PUBLICATION DATE NOVEMBER 2013 ELIDEL (ATOPIC DERMATITIS) FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC295DFR PUBLICATION DATE NOVEMBER 2013 ELIDEL (ATOPIC DERMATITIS) Executive Summary The below mentioned table presents key metrics for Elidel in the major pharmaceutical markets: the

More information

A Cross-Sectional Survey of a Dermatology Outpatient Service in Malta

A Cross-Sectional Survey of a Dermatology Outpatient Service in Malta Original Article A Cross-Sectional Survey of a Dermatology Outpatient Service in Malta Susan Aquilina, Andrew Amato Gauci, Michael J Boffa Abstract A survey of the outpatient service provided by a consultant

More information

Cost-Motivated Treatment Changes in Commercial Claims:

Cost-Motivated Treatment Changes in Commercial Claims: Cost-Motivated Treatment Changes in Commercial Claims: Implications for Non- Medical Switching August 2017 THE MORAN COMPANY 1 Cost-Motivated Treatment Changes in Commercial Claims: Implications for Non-Medical

More information

The Economic Burden of Hypercholesterolaemia

The Economic Burden of Hypercholesterolaemia The Economic Burden of Hypercholesterolaemia November 2018 TABLE OF CONTENTS Acronyms 3 Executive Summary 4 Introduction 5 Approach 5 Structure of the report 5 Economic burden of hypercholesterolaemia

More information

Setting The setting was primary care. The economic study was carried out in the UK and the USA.

Setting The setting was primary care. The economic study was carried out in the UK and the USA. Validation of venous leg ulcer guidelines in the United States and United Kingdom McGuckin M, Waterman R, Brooks J, Cherry G, Porten L, Hurley S, Kerstein M D Record Status This is a critical abstract

More information

Clinical Policy: Rivastigmine (Exelon) Reference Number: CP.PMN.101 Effective Date: Last Review Date: 02.18

Clinical Policy: Rivastigmine (Exelon) Reference Number: CP.PMN.101 Effective Date: Last Review Date: 02.18 Clinical Policy: (Exelon) Reference Number: CP.PMN.101 Effective Date: 03.01.17 Last Review Date: 02.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Dupixent) Reference Number: CP.HNMC.208 Effective Date: 04.11.17 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy

More information

Removing Barriers To Dermatologic Care Of The Uninsured

Removing Barriers To Dermatologic Care Of The Uninsured Removing Barriers To Dermatologic Care Of The Uninsured Texas Dermatological Society Cloyce L. Stetson, M.D., President; Laura Madole, Executive Director The Free Clinic Fiona Prabhu, M.D., Medical Director

More information

Global Influenza Vaccine Market: Industry Analysis & Outlook

Global Influenza Vaccine Market: Industry Analysis & Outlook Industry Research by Koncept Analytics Global Influenza Vaccine Market: Industry Analysis & Outlook ----------------------------------------- January 2017 1 Executive Summary Influenza, also known as flu,

More information

Quality ID #224 (NQF 0562): Melanoma: Overutilization of Imaging Studies in Melanoma National Quality Strategy Domain: Efficiency and Cost Reduction

Quality ID #224 (NQF 0562): Melanoma: Overutilization of Imaging Studies in Melanoma National Quality Strategy Domain: Efficiency and Cost Reduction Quality ID #224 (NQF 0562): Melanoma: Overutilization of Imaging Studies in Melanoma National Quality Strategy Domain: Efficiency and Cost Reduction 2018 OPTIONS F INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE

More information

Measure #131 (NQF 0420): Pain Assessment and Follow-Up National Quality Strategy Domain: Community/Population Health*

Measure #131 (NQF 0420): Pain Assessment and Follow-Up National Quality Strategy Domain: Community/Population Health* Measure #131 (NQF 0420): Pain Assessment and Follow-Up National Quality Strategy Domain: Community/Population Health* *Please note that PQRS 131 is incorrectly listed under the Communication and Care Coordination

More information

UNIVERSITY OF MICHIGAN HOSPITALS AND HEALTH CENTERS. Delineation of Privileges Department of Dermatology

UNIVERSITY OF MICHIGAN HOSPITALS AND HEALTH CENTERS. Delineation of Privileges Department of Dermatology University of Michigan Hospitals and Health Centers UNIVERSITY OF MICHIGAN HOSPITALS AND HEALTH CENTERS Delineation of Privileges Department of Dermatology Name: Please Print or Type LEVEL I CORE PRIVILEGES

More information

The Cost Of Functional Dyspepsia Results From A Large US Employer Database

The Cost Of Functional Dyspepsia Results From A Large US Employer Database European ISPOR Meeting Copenhagen, Denmark October 30, 2006 The Cost Of Functional Dyspepsia Results From A Large US Employer Database Researchers: Stephen George, MS, RPh 1, Nathan Kleinman, PhD 2, Richard

More information

The ALS Association Mid-America Chapter 87 people in Nebraska have ALS. Every 90 minutes, someone is diagnosed with or passes away from ALS.

The ALS Association Mid-America Chapter 87 people in Nebraska have ALS. Every 90 minutes, someone is diagnosed with or passes away from ALS. HEALTH FACTS The ALS Association Mid-America Chapter 87 people in Nebraska have ALS. Every 90 minutes, someone is diagnosed with or passes away from ALS. Alzheimer s Association Nebraska Chapter 5.5 million

More information

Long Life Unlimited 1/31/18

Long Life Unlimited 1/31/18 Long Life Unlimited 1/31/18 Cincinnati District Office 6751 Steger Drive Cincinnati, OH 45237 Telephone: (513) 679-2700 FAX: (513) 679-2772 WARNING LETTER 533282 January 31, 2018 VIA UPS Long Life Unlimited,

More information

THE INTEGUMENTARY SYSTEM. Body Membranes & Skin

THE INTEGUMENTARY SYSTEM. Body Membranes & Skin THE INTEGUMENTARY SYSTEM Body Membranes & Skin TYPES OF MEMBRANES Epithelial Membranes includes layer of epithelial cells and connective tissue Serous Cutaneous Mucous Connective Tissue Membranes solely

More information

Chapter 6: Healthcare Expenditures for Persons with CKD

Chapter 6: Healthcare Expenditures for Persons with CKD Chapter 6: Healthcare Expenditures for Persons with CKD In this 2017 Annual Data Report (ADR), we introduce information from the Optum Clinformatics DataMart for persons with Medicare Advantage and commercial

More information